JP2012504110A - 疾患治療組成物 - Google Patents

疾患治療組成物 Download PDF

Info

Publication number
JP2012504110A
JP2012504110A JP2011528278A JP2011528278A JP2012504110A JP 2012504110 A JP2012504110 A JP 2012504110A JP 2011528278 A JP2011528278 A JP 2011528278A JP 2011528278 A JP2011528278 A JP 2011528278A JP 2012504110 A JP2012504110 A JP 2012504110A
Authority
JP
Japan
Prior art keywords
agent
patient
antibody
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011528278A
Other languages
English (en)
Japanese (ja)
Inventor
フランク・オステロート
ジルケ・アイグナー
クリストフ・ウーヘレク
アンドレア・ワルテンベルク−デマンド
アナトリー・ルドネフ
ミヒャエル・ソルダン
クリストフ・ブルエヒャー
ベンジャミン・デルケン
シャンタール・ツバー
グレゴール・シュルツ
ニクラス・セロス
Original Assignee
バイオテスト・アクチエンゲゼルシヤフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Priority claimed from GB0817809A external-priority patent/GB0817809D0/en
Priority claimed from PCT/EP2009/052809 external-priority patent/WO2009121690A1/en
Priority claimed from PCT/EP2009/052811 external-priority patent/WO2009124815A1/en
Priority claimed from PCT/EP2009/052810 external-priority patent/WO2009112502A1/en
Application filed by バイオテスト・アクチエンゲゼルシヤフト filed Critical バイオテスト・アクチエンゲゼルシヤフト
Publication of JP2012504110A publication Critical patent/JP2012504110A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011528278A 2008-09-29 2009-08-31 疾患治療組成物 Pending JP2012504110A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817810.5 2008-09-29
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817809A GB0817809D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817811.3 2008-09-29
GB0817809.7 2008-09-29
PCT/EP2009/052809 WO2009121690A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052811 2009-03-10
PCT/EP2009/052811 WO2009124815A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052809 2009-03-10
EPPCT/EP2009/052810 2009-03-10
PCT/EP2009/061210 WO2010034590A1 (en) 2008-09-29 2009-08-31 Composition for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015097888A Division JP6154847B2 (ja) 2008-09-29 2015-05-13 疾患治療組成物

Publications (1)

Publication Number Publication Date
JP2012504110A true JP2012504110A (ja) 2012-02-16

Family

ID=41138980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011528278A Pending JP2012504110A (ja) 2008-09-29 2009-08-31 疾患治療組成物
JP2015097888A Expired - Fee Related JP6154847B2 (ja) 2008-09-29 2015-05-13 疾患治療組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015097888A Expired - Fee Related JP6154847B2 (ja) 2008-09-29 2015-05-13 疾患治療組成物

Country Status (16)

Country Link
US (1) US20110229465A1 (enExample)
JP (2) JP2012504110A (enExample)
KR (1) KR20110061630A (enExample)
CN (1) CN102215867B (enExample)
AU (1) AU2009296078B2 (enExample)
BR (1) BRPI0919489A2 (enExample)
CA (1) CA2738598C (enExample)
CR (1) CR20110226A (enExample)
DK (1) DK2341937T3 (enExample)
ES (1) ES2528419T3 (enExample)
IL (1) IL211904A (enExample)
MX (1) MX2011003335A (enExample)
PT (1) PT2341937E (enExample)
RU (1) RU2531548C2 (enExample)
SG (1) SG194362A1 (enExample)
WO (1) WO2010034590A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549237A (ja) * 2020-11-10 2023-11-22 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
GB202017681D0 (en) * 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525156A (ja) * 2003-03-21 2007-09-06 ビオテスト・アーゲー 免疫抑制作用を有するヒト化抗ｃｄ４抗体

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
DE69126301T2 (de) * 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE204299T1 (de) * 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
WO2001093908A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
CA2434972C (en) * 2001-01-16 2010-06-08 Vascular Therapies, Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
NZ528250A (en) * 2001-03-07 2006-09-29 Childrens Medical Center Method to screen peptide display libraries using minicell display
CN1247258C (zh) * 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
ES2392287T3 (es) * 2001-12-04 2012-12-07 Theramab Llc Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
ME00426B (me) * 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
US20070270431A1 (en) * 2004-09-29 2007-11-22 Kowa Co., Ltd. Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
US8663634B2 (en) * 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US20070218062A1 (en) * 2006-03-16 2007-09-20 Genentech, Inc. Methods of treating lupus using CD4 antibodies
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
ES2351456B1 (es) * 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525156A (ja) * 2003-03-21 2007-09-06 ビオテスト・アーゲー 免疫抑制作用を有するヒト化抗ｃｄ４抗体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN5012000821; ＬＵＧＧＥＮ　Ｍ　Ｅ: 'ＲＥＳＵＬＴＳ　ＯＦ　Ａ　ＰＨＡＳＥ　ＩＩ，ＤＯＵＢＬＥ-ＢＬＩＮＤ，ＲＡＮＤＯＭＩＺＥＤ　ＳＴＵＤＹ　ＯＦ　Ａ　ＮＯＮＤＥＰＬＥＴＩＮＧ　ＡＮＴＩ-ＣＤ４　以下備考' ＡＮＮＡＬＳ　ＯＦ　ＴＨＥ　ＲＨＥＵＭＡＴＩＣ　ＤＩＳＥＡＳＥＳ Ｖ６２　Ｎ　ＳＵＰＰＬ．１, 20030701, Ｐ９９, ＢＲＩＴＩＳＨ　ＭＥＤＩＣＡＬ　ＡＳＳＯＣＩＡＴＩＯＮ *
JPN5012000822; ＳＯＵＮＤＡＲＡＲＡＪＡＮ　Ｄ: 'ＣＬＩＮＩＣＡＬ　ＡＮＤ　ＩＭＭＵＮＯＬＯＧＩＣＡＬ　ＥＦＦＥＣＴＳ　ＯＦ　Ａ　ＰＲＩＭＡＴＩＺＥＤ　ＡＮＴＩ　ＣＤ４　ＡＮＴＩＢＯＤＹ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＡＬＬＥＲＧＹ　ＡＮＤ　ＣＬＩＮＩＣＡＬ　ＩＭＭＵＮＯＬＯＧＹ Ｖ９９　Ｎ１　ＰＡＲＴ２, 19970101, Ｐ　Ｓ１９３, ＭＯＳＢＹ-ＹＥＡＲＬＹ　ＢＯＯＫ *
JPN5012000824; ＲＡＣＡＤＯＴ　Ｅ: 'ＩＭＭＵＮＯＬＯＧＩＣＡＬ　ＦＯＬＬＯＷ-ＵＰ　ＯＦ　１７　ＰＡＴＩＥＮＴＳ　ＷＩＴＨ　ＲＨＥＵＭＡＴＯＩＤ　ＡＲＴＨＲＩＴＩＳ　ＴＲＥＡＴＥＤ　以下備考' ＣＬＩＮＩＣＡＬ　ＡＮＤ　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＰＨＥＵＭＡＴＯＬＯＧＹ Ｖ１０　Ｎ４, 19920101, Ｐ３６５-３７４, ＰＡＣＩＮＩ *
JPN5012000825; ＷＥＮＤＬＩＮＧ　Ｄ: 'ＴＲＥＡＴＭＥＮＴ　ＯＦ　ＲＨＥＵＭＡＴＯＩＤ　ＡＲＴＨＲＩＴＩＳ　ＷＩＴＨ　ＡＮＴＩ　ＣＤ４　ＭＯＮＯＣＬＯＮＡＬ　ＡＮＴＩＢＯＤＹ．以下備考' ＣＬＩＮＩＣＡＬ　ＲＨＥＵＭＡＴＯＬＯＧＹ Ｖ１１　Ｎ４, 19921201, Ｐ５４２-５４７, ＡＣＴＡ　ＭＥＤＩＣＡ　ＢＥＬＧＩＣＡ *
JPN6014002679; Ｊ　Ｅｘｐ　Ｍｅｄ，　ｖｏｌ．２００，　ｐ．２７７-２８５　（２００４） *
JPN6014002684; Ｅｕｒ　Ｊ　Ｉｍｍｕｎｏｌ，　ｖｏｌ．３７，　ｐ．１２１７-１２２３　（２００７ *
JPN6014002685; Ｂｌｏｏｄ，　ｖｏｌ．１０８，　ｐ．２５３-２６１　（２００６） *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549237A (ja) * 2020-11-10 2023-11-22 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物
JP7575598B2 (ja) 2020-11-10 2024-10-29 レオポルド エムテーイクス ゲーエムベーハー 医薬組成物

Also Published As

Publication number Publication date
ES2528419T3 (es) 2015-02-09
BRPI0919489A2 (pt) 2015-12-01
AU2009296078A1 (en) 2010-04-01
MX2011003335A (es) 2011-04-27
IL211904A (en) 2016-03-31
HK1154797A1 (en) 2012-05-04
RU2011117293A (ru) 2012-11-10
SG194362A1 (en) 2013-11-29
DK2341937T3 (en) 2015-02-09
JP6154847B2 (ja) 2017-06-28
AU2009296078B2 (en) 2015-08-20
IL211904A0 (en) 2011-06-30
CN102215867A (zh) 2011-10-12
WO2010034590A1 (en) 2010-04-01
KR20110061630A (ko) 2011-06-09
CN102215867B (zh) 2017-04-19
CA2738598C (en) 2017-11-21
PT2341937E (pt) 2015-02-18
US20110229465A1 (en) 2011-09-22
RU2531548C2 (ru) 2014-10-20
JP2015172060A (ja) 2015-10-01
CA2738598A1 (en) 2010-04-01
CR20110226A (es) 2011-12-05

Similar Documents

Publication Publication Date Title
JP6154847B2 (ja) 疾患治療組成物
JP5597553B2 (ja) 疾患治療剤
JP5604311B2 (ja) 疾患治療剤
JP5795167B2 (ja) 疾患治療剤
JP2024513262A (ja) Ｎｋｐ４６及びｃｄ３８を標的とする二重特異性抗体、並びにその使用方法
JP2025504529A (ja) がんの治療のための併用療法
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
EP2341937B1 (en) Composition for treating disease
WO2020061571A1 (en) Anti-il-33 antibody for use in treating eosinophilic asthma
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
CN112439060B (zh) Pd-l1免疫疗法的新用途
CN120202021A (zh) 用于治疗t淋巴细胞介导的疾病的方法
HK1154797B (en) Composition for treating disease
TW202302146A (zh) 使用抗baffr抗體治療全身性紅斑狼瘡
JP2024513264A (ja) Ｎｋｐ４６及びｇｐｃ３を標的とする二重特異性抗体、並びにその使用方法
JP2023548848A (ja) ループスを処置するための方法および組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150113